Appili Therapeutics Delists from TSX, Transfers to NEX
News related to:Appili Therapeutics · 1 min read
Halifax, Nova Scotia, Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, announced on September 29, 2026, that it has applied to voluntarily delist its Class A common shares from the Toronto Stock Exchange (TSX) and transfer its listing to the NEX Board of the TSX Venture Exchange (NEX). The company’s shares will be delisted from the TSX at the close of markets on October 2, 2026, and will commence trading on the NEX on October 5, 2026.
According to the release, the delisting is due to the company’s failure to meet the TSX’s continued listing requirements. The trading symbol for the company will change from "APLI" to "APLI.H," with the extension "H" differentiating NEX listings from those on the TSX. There is no change in the company’s name, CUSIP number, or capital structure. The company’s management believes that the move to the NEX will provide a more appropriate listing for its current market capitalization and shareholder base.
Appili Therapeutics, founded with the mission to solve life-threatening infections, is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. The company is led by a proven management team dedicated to addressing urgent infections with unmet medical needs.
The release also notes that forward-looking information contained within the document is subject to various risks and uncertainties that could cause actual results to differ materially from those projected. Shareholders are advised to review the company’s filings with the Canadian securities regulators for more detailed information.
This move by Appili Therapeutics marks a significant shift in its market presence, reflecting the company’s ongoing efforts to adapt to changing market dynamics and regulatory environments.